Related Experiment Video
Updated: Jun 15, 2026

07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle
Zhi Ding1, Suzanne M Bal, Stefan Romeijn
1Division of Drug Delivery Technology Leiden/Amsterdam Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Pharmaceutical Research
|March 19, 2010
Summary
Transcutaneous immunization (TCI) with diphtheria toxoid (DT) showed enhanced antibody titers in mice when combined with microneedle pretreatment and cholera toxin adjuvant. Vesicle formulation did not improve immunogenicity.
Area of Science:
- Vaccinology
- Nanotechnology
- Immunology
Background:
- Transcutaneous immunization (TCI) offers a needle-free vaccine delivery route.
- Microneedle arrays can enhance antigen penetration through the skin.
- Diphtheria toxoid (DT) is a key component in routine vaccinations.
Purpose of the Study:
- To evaluate the immunogenicity of DT formulated in cationic liposomes and anionic vesicles using TCI.
- To assess the impact of microneedle array pretreatment on TCI efficacy.
- To investigate the role of cholera toxin as an adjuvant in TCI.
Main Methods:
- Preparation and characterization of DT-loaded liposomes and vesicles.
- Application of formulations onto intact or microneedle-pretreated mouse skin.
- Measurement of IgG and neutralizing antibody titers, and assessment of dendritic cell activity.
Main Results:
- Stable liposomes (~150 nm) and vesicles (~100 nm) with high DT association were prepared.
- Substantial antibody titers were achieved only with microneedle pretreatment during TCI.
- Cholera toxin significantly augmented immune responses, while vesicle formulations showed limited enhancement.
Conclusions:
- Microneedle pretreatment is crucial for effective TCI of DT.
- Cholera toxin acts as a potent adjuvant, boosting TCI immunogenicity.
- Antigen association with vesicles did not improve topical DT immunogenicity.
